<DOC>
	<DOC>NCT01761123</DOC>
	<brief_summary>the purpose of the study is to determine the safety and tolerability of VXA-A1.1, an adjuvanted adenoviral based influenza vaccine, when delivery is targeted to the ileum, using a radio controlled capsule. The secondary objective is to evaluate the immune response (cellular and humoral) of two doses of VXA-A1.1 oral vaccine.</brief_summary>
	<brief_title>Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Able and willing to complete informed consent Healthy, as established by medical history, physical exam, and laboratory assessments Has normal bowel movements Willing to abstain from caffeine and xanthine containing substances for 24 hours before procedure until after discharge Not able to donate up to 550 ml of blood over several months Exposure to an investigational drug or vaccine 8 weeks prior to study Abnormal ECG findings History of irritable bowl or any other inflammatory gastrointestinal disorder Any individual with increased risk for bowl obstruction Radiation exposure above target values 50 mSv within the past 30 days or a cumulative dose above 150 mSV in the past 12 months History of substance abuse Subject unwilling to use an approved method of contraception during study and for 2 months after study Positive for HCV, HIV, or HBV Presence of implantable device that is sensitive to radio frequencies ( e.g. pacemakers) History of autoimmune disorder, or an immunosuppressive disorder Stool sample with occult blood at baseline Any other medical, psychiatric, social condition, or occupation, in the judgement of the investigator is a contraindication to the compliance of the protocol or informed consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention of Influenza</keyword>
</DOC>